Skip to main content

Table 4 Incidence of adverse events (N = 93)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Adverse event ≥Grade 1 ≥Grade 3
N % N %
Neutropenia 89 95.7 56 60.2
Leukopenia 89 95.7 22 23.7
Thrombocytopenia 12 12.9 0 0
Anemia 44 47.3 7 7.5
AST 27 29.0 0 0
ALT 32 34.4 1 1.1
Anorexia 60 64.5 6 6.5
Diarrhea 59 63.4 9 9.7
Nausea 61 65.6 0 0
Stomatitis 62 66.7 3 3.2
Vomiting 36 38.7 0 0
Fatigue 66 71.0 5 5.4
Cholinergic syndrome 18 19.4 0 0
Febrile neutropenia 1 1.1 1 1.1
Sepsis 2 2.2 2 2.2
Interstitial pneumonia 1 1.1 0 0
Hypertension 10 10.8 1 1.1
Bleeding 7 7.5 0 0
Pulmonary artery thrombosis 1 1.1 1 1.1
Pulmonary embolism 1 1.1 0 0
Embolism venous 1 1.1 1 1.1
Gastrointestinal perforation 2 2.2 2 2.2